Impact and management of breakthrough pain in cancer

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 1, 2009, Pages 1-6

  Zeppetella, Giovambattista ^a,b  

^a FRCP ^*  (United Kingdom)

^b FRCP   (United Kingdom)

Author keywords

Breakthrough pain; Cancer; Pain; Palliative care

Indexed keywords

NARCOTIC ANALGESIC AGENT;

HUMAN; METHODOLOGY; NEOPLASM; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; REVIEW;

ANALGESICS, OPIOID; HUMANS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE;

EID: 67650333512     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283260658     Document Type: Article

References (44)

1. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2008. doi: 10.101 6/j.ejpain. 2008.06.014 [Epub ahead of print].
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41:273-281.
3. Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 1999;17:391-401.
4. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes: IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999;82:263-274.
5. Zeppetella G, Ribeiro MDC. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 2003;4:493-502.
6. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Sem Oncol 1997;5 (Suppl 16) : S16-7-12.
7. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-134.
8. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Sympt Manage 2000;20:87-92.
9. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64.
10. Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 2001;15:9-18.
11. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992;50:151-155.
12. Bruera E, Scholler T, Wenk R, et al. A prospective multicentre assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995;10:348-355.
13. Bruera E, Fainsinger R, MacEachern T, et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates: a preliminary report. Pain 1992;50:75-77.
14. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44.
15. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Sympt Manage 2003;25:9-18.
16. World Health Organisation. Cancer pain relief. Geneva: WHO; 1986.
17. Moore A, Collins S, Carroll D, et al. Single dose paracetamol (acetaminophen), with and without codeine, for postoperative pain. Cochrane Database Syst Rev 1998: CD001547. doi: 10.1002/14651858. CD0011547.
18. McNicol E, Strassels S, Goudas L, et al. Nonsteroidal anti-inflammatory drugs, alone or combine with opioids, for cancer pain: a systematic review. J Clin Oncol 2004;22:1975-1992.
19. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005: CD001133. doi: 10.1002/14651858. CD001133.pub2.
20. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005:CD005454. doi: 10.1002/14651858. CD005454.
21. Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004;28:505-510.
22. Enting RH, Oldenmenger WH, van der Rijt CC, et al. Nitrous oxide is not beneficial for breakthrough cancer pain. Palliat Med 2002;16:257-259.
23. Mercadante S, Arcuri E, Tirelli W, Casuccio A. The analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-252.
24. del Rosario MA, Martin AS, Ortega JJ, Feria M. Temporary sedation with midazolam for control of severe incident pain. J Pain Symptom Manage 2001;21:177-178.
25. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. P & T 2005;30:354-361.
26. Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2004;28:619-625.
27. Hanks GW, De Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-593.
28. Freye E, Levy JV, Braun D. Effervescent morphine results in faster pain relief of breakthrough pain in patients compared to immediate release morphine sulphate tablets. Pain Pract 2007;7:324-331.
29. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006;32:175-179.
30. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27:352-359.
31. Enting RH, Mucchiano C, Oldenmenger WH, et al. The 'pain pen' for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage 2005;29:213-217.
32. Walker G, Wilcock A, Manderson C, et al. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 2003;17:219-221.
33. Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage 1996;11:378-387.
34. Davis MP, Walsh D, LeGrand SB, Naughton M. Symptom control in cancer patients: the clinical pharmacology and therapeutic role of suppositories and rectal suspensions. Support Care Cancer 2002;10:117-138.
35. Worsley MH, MacLeod AD, Brodie MJ, et al. Inhaled fentanyl as a method of analgesia. Anaesthesia 1990;45:449-451.
36. Zeppetella G. Nebulized and intranasal fentanyl in the management of cancerrelated breakthrough pain. Palliat Med 2000;14:57-58.
37. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;46:759-770.
38. Duncan A. The use of fentanyl and alfentanil sprays for episodic pain. Palliat Med 2002;16:550.
39. Fitzgibbon D, Morgan D, Dockter D, et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 2003;106:309-315.
40. Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005;59:249-253.
41. Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Pall Care 2001;8:6-9.
42. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006: CD004311.
43. Webster LR. Fentanyl buccal tablets. Expert Opin Investig Drugs 2006;15:1469-1473.
44. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of break- through pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-334.